Table 1.
Baseline factors of the total cohort and groups with high and low TMB
| Total N = 75 |
Low TMB (N = 38) |
High TMB (N = 37) |
P value | |
|---|---|---|---|---|
| Age (Y) | ||||
| < 69 | 38 (50.7%) | 20 (52.6%) | 18 (48.6%) | 0.730 |
| ≥ 69 | 37 (49.3%) | 18 (47.4%) | 19 (51.4%) | |
| Gender | ||||
| Male | 57 (76.0%) | 28 (73.7%) | 29 (78.4%) | 0.634 |
| Female | 18 (24.0%) | 10 (26.3%) | 8 (21.6%) | |
| Race | ||||
| White | 67 (89.3%) | 31 (81.6%) | 36 (97.3%) | 0.015 |
| Black | 7 (9.3%) | 7 (18.4%) | 0 (0.0%) | |
| Asian | 1 (1.3%) | 0 (0.0%) | 1 (2.7%) | |
| Diagnosis Year | ||||
| 2005–2010 | 30 (40.0%) | 16 (42.1%) | 14 (37.8%) | 0.706 |
| 2011–2013 | 45 (60.0%) | 22 (57.9%) | 23 (62.2%) | |
| BMI (kg/m2) | ||||
| < 26.6 | 34 (45.3%) | 17 (44.7%) | 17 (45.9%) | 0.906 |
| ≥ 26.6 | 35 (46.7%) | 18 (47.4%) | 17 (45.9%) | |
| Unknown | 6 (8.0%) | 3 (7.9%) | 3 (8.1%) | |
| p T stage | ||||
| pT2 | 24 (32.0%) | 11 (28.9%) | 13 (35.1%) | 0.676 |
| pT3–4 | 43 (57.3%) | 22 (57.9%) | 21 (56.8%) | |
| Unknown | 8 (10.7%) | 5 (13.2%) | 3 (8.1%) | |
| p N stage | ||||
| pN0 | 42 (56.0%) | 19 (50.0%) | 23 (62.2%) | 0.373 |
| pN1–2 | 21 (28.0%) | 12 (31.6%) | 9 (24.3%) | |
| Unknown | 12 (16.0%) | 7 (18.4%) | 5 (13.5%) | |
| Stage | ||||
| Stage II | 28 (37.3%) | 12 (31.6%) | 16 (43.2%) | 0.296 |
| Stage III | 47 (62.7%) | 26 (68.4%) | 21 (56.8%) | |
| Clustering Group | ||||
| Group A | 24 (32.0%) | 8 (21.1%) | 16 (43.2%) | 0.039 |
| Group B | 51 (68.0%) | 30 (78.9%) | 21 (56.8%) | |
TMB Tumor mutation burden; BMI Body mass index